Subjects will receive either TOUJEO, LANTUS, or LEVEMIR – all commercially available. For insulin naïve patients who have been on two or more oral agents of GLP-1agonists and are still uncontrolled. Uncontrolled = A1c between 8 and 11% MUST NOT have used insulins in the past One year study DIABETES TESTING SUPPLIES AND STUDY DRUG PROVIDED AT NO COST “Real World” pragmatic trial to assess the clinical and health outcomes of Toujeo compared to other available insulins for initiation of therapy in insulin naïve patients with uncontrolled T2DM. Determining if those on Toujeo have fewer hypoglycemic events while still reaching A1c targets. Most study participants receive stipend for each visit completed, in addition to safety assessments (labs, EKGs, Physician exams, etc).